[go: up one dir, main page]

PL2968650T3 - Preparaty do oczu do dostarczania leku do tylnego fragmentu oka - Google Patents

Preparaty do oczu do dostarczania leku do tylnego fragmentu oka

Info

Publication number
PL2968650T3
PL2968650T3 PL14724204T PL14724204T PL2968650T3 PL 2968650 T3 PL2968650 T3 PL 2968650T3 PL 14724204 T PL14724204 T PL 14724204T PL 14724204 T PL14724204 T PL 14724204T PL 2968650 T3 PL2968650 T3 PL 2968650T3
Authority
PL
Poland
Prior art keywords
eye
drug
delivery
posterior segment
ocular formulations
Prior art date
Application number
PL14724204T
Other languages
English (en)
Inventor
David P. Bingaman
Paul G. Chaney
Martin B. Wax
Original Assignee
Panoptica Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Panoptica Inc filed Critical Panoptica Inc
Publication of PL2968650T3 publication Critical patent/PL2968650T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/427Thiazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965Non-condensed pyrazines
    • A61K31/497Non-condensed pyrazines containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40Cyclodextrins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/02Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL14724204T 2013-03-14 2014-03-14 Preparaty do oczu do dostarczania leku do tylnego fragmentu oka PL2968650T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361784681P 2013-03-14 2013-03-14
PCT/US2014/027589 WO2014152661A1 (en) 2013-03-14 2014-03-14 Ocular formulations for drug-delivery to the posterior segment of the eye
EP14724204.4A EP2968650B1 (en) 2013-03-14 2014-03-14 Ocular formulations for drug-delivery to the posterior segment of the eye

Publications (1)

Publication Number Publication Date
PL2968650T3 true PL2968650T3 (pl) 2019-05-31

Family

ID=50625096

Family Applications (1)

Application Number Title Priority Date Filing Date
PL14724204T PL2968650T3 (pl) 2013-03-14 2014-03-14 Preparaty do oczu do dostarczania leku do tylnego fragmentu oka

Country Status (22)

Country Link
US (8) US9446026B2 (pl)
EP (2) EP2968650B1 (pl)
JP (3) JP6542193B2 (pl)
KR (2) KR20210132205A (pl)
CN (2) CN111789814B (pl)
AU (3) AU2014239252B2 (pl)
BR (1) BR112015021334B1 (pl)
CA (1) CA2900840C (pl)
DK (1) DK2968650T3 (pl)
ES (1) ES2710152T3 (pl)
HU (1) HUE042528T2 (pl)
IL (2) IL240510B (pl)
MX (2) MX360888B (pl)
PH (2) PH12015501938B1 (pl)
PL (1) PL2968650T3 (pl)
PT (1) PT2968650T (pl)
RU (2) RU2768489C2 (pl)
SA (1) SA516380321B1 (pl)
SG (2) SG11201507316UA (pl)
TR (1) TR201901462T4 (pl)
WO (1) WO2014152661A1 (pl)
ZA (2) ZA201505447B (pl)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3142049C (en) 2012-09-12 2023-08-29 Novaliq Gmbh Semifluorinated alkane compositions
CA2997744C (en) 2012-09-12 2019-12-31 Novaliq Gmbh Compositions comprising mixtures of semifluorinated alkanes
MA56220A (fr) * 2014-09-17 2022-04-20 Panoptica Inc Formulations oculaires permettant l'administration de médicament et la protection du segment antérieur de l'oeil
WO2017055454A1 (en) 2015-09-30 2017-04-06 Novaliq Gmbh Semifluorinated compounds and their compositions
CA3016602C (en) 2016-03-11 2025-05-06 Georgia Pacific Gypsum Llc Plasterboard, Systems and Processes
PL3612228T3 (pl) 2017-04-21 2024-04-08 Dermaliq Therapeutics, Inc. Kompozycje jodu
US11278503B2 (en) 2017-05-12 2022-03-22 Novaliq Gmbh Pharmaceutical compositions comprising semifluorinated alkanes for the treatment of contact lense-related conditions
RU2652342C1 (ru) * 2017-07-13 2018-04-25 Наталья Александровна Гаврилова Композиция для лечения ретинальной неоваскуляризации в эксперименте и способ лечения с ее использованием
SG11202002640YA (en) 2017-09-27 2020-04-29 Novaliq Gmbh Ophthalmic compositions comprising latanoprost for use in the treatment of ocular diseases
US11896559B2 (en) 2017-10-04 2024-02-13 Novaliq Gmbh Opthalmic compositions comprising F6H8
WO2019206956A1 (en) 2018-04-27 2019-10-31 Novaliq Gmbh Ophthalmic compositions comprising tafluprost for the treatment of glaucoma
MY206642A (en) 2018-10-12 2024-12-30 Novaliq Gmbh Ophthalmic composition for treatment of dry eye disease
US12397039B2 (en) 2019-02-13 2025-08-26 Novaliq Gmbh Compositions and methods for the treatment of ocular neovascularization
AT522609B1 (de) 2019-05-28 2022-06-15 Miba Frictec Gmbh Reibvorrichtung
AU2020340561A1 (en) 2019-09-06 2022-03-31 Novaliq Gmbh Ophthalmic composition for the treatment of uveitis
JP2022548071A (ja) * 2019-09-13 2022-11-16 アメリカ合衆国 網膜変性を治療するための新薬の開発につながる標的
AU2022268925A1 (en) 2021-05-03 2023-11-16 Avilar Therapeutics, Inc. Potent asgpr-binding compounds for the degradation of immunoglobulins and other proteins
WO2025058571A1 (en) * 2023-09-15 2025-03-20 Agency For Science, Technology And Research Polymer composition comprising a thermogelling polymer and a tyrosine kinase inhibitor, and related methods thereof

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3609795A (en) * 1994-10-10 1996-05-02 Novartis Ag Ophthalmic and aural compositions containing diclofenac potassium
JPH10203960A (ja) * 1997-01-24 1998-08-04 Ofutekusu:Kk 点眼液組成物
UA60365C2 (uk) 1998-06-04 2003-10-15 Пфайзер Продактс Інк. Похідні ізотіазолу, спосіб їх одержання, фармацевтична композиція та спосіб лікування гіперпроліферативного захворювання у ссавця
US6239113B1 (en) 1999-03-31 2001-05-29 Insite Vision, Incorporated Topical treatment or prevention of ocular infections
US6254860B1 (en) 1999-04-13 2001-07-03 Allergan Sales, Inc. Ocular treatment using cyclosporin-A derivatives
AU6870800A (en) * 1999-09-06 2001-04-10 Ono Pharmaceutical Co. Ltd. Preventive and therapeutic agents for eye diseases
YU36403A (sh) 2000-11-28 2006-08-17 Pfizer Products Inc. Soli izotiazol-4-karboksamida kao anti-hiperproliferacioni agensi
AU2003281664A1 (en) 2002-07-25 2004-02-16 Pfizer Products Inc. Isothiazole derivatives useful as anticancer agents
CN1533553A (zh) * 2002-08-29 2004-09-29 ��˹��ķ��ʽ���� 视觉辅助网络服务器,视觉辅助网络系统,视觉辅助方法,视觉辅助系统,视觉缺陷告知系统,视觉缺陷告知程序,视觉缺陷告知方法,色彩辨别辅助系统,色彩辨别辅助程序,以及色彩辨别辅助方法
US20050074497A1 (en) * 2003-04-09 2005-04-07 Schultz Clyde L. Hydrogels used to deliver medicaments to the eye for the treatment of posterior segment diseases
US20050234018A1 (en) 2004-04-15 2005-10-20 Allergan, Inc. Drug delivery to the back of the eye
WO2005102327A1 (en) * 2004-04-20 2005-11-03 Pfizer Products Inc. Dosage forms and methods of treatment using vegfr inhibitors
US7483533B2 (en) * 2004-08-05 2009-01-27 King Fahd University Of Petroleum Elliptic polynomial cryptography with multi x-coordinates embedding
JP2006111621A (ja) * 2004-09-15 2006-04-27 Santen Pharmaceut Co Ltd ピレノキシン懸濁型点眼剤
EP1827373B1 (en) * 2004-11-09 2008-12-03 Novagali Pharma SA Ophthalmic emulsions containing prostaglandins
AU2006254825A1 (en) * 2005-06-08 2006-12-14 Targegen, Inc. Methods and compositions for the treatment of ocular disorders
JP2007012937A (ja) * 2005-06-30 2007-01-18 Seiko Epson Corp 表示ドライバ
JP2007011785A (ja) * 2005-06-30 2007-01-18 Toshiba Corp 情報処理装置、およびタッチパネルの振動制御方法
US7893040B2 (en) 2005-07-22 2011-02-22 Oculis Ehf Cyclodextrin nanotechnology for ophthalmic drug delivery
JP5247453B2 (ja) * 2005-10-10 2013-07-24 ノバガリ ファルマ エスア プロスタグランジン含有眼科用カチオン性水中油型エマルジョン
DE102006051512A1 (de) * 2005-12-06 2007-06-14 Pari GmbH Spezialisten für effektive Inhalation Pharmazeutische Medikamentenzusammensetzungen mit Cyclosporin
AR059066A1 (es) * 2006-01-27 2008-03-12 Amgen Inc Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf)
CA2679066A1 (en) * 2007-02-22 2008-08-28 Othera Holding, Inc. Hydroxylamine compounds and methods of their use
CN101848715A (zh) * 2007-08-09 2010-09-29 千寿制药株式会社 含吡诺克辛的二液性滴眼剂
US20100010082A1 (en) * 2008-07-09 2010-01-14 Aspreva International Ltd. Formulations for treating eye disorders
JP2010265261A (ja) * 2009-04-17 2010-11-25 Santen Pharmaceut Co Ltd レボカバスチン懸濁型点眼剤
JP2012250918A (ja) * 2011-05-31 2012-12-20 Rohto Pharmaceutical Co Ltd ニューキノロン剤含有水性組成物
CA2865132A1 (en) 2012-02-22 2013-08-29 Trustees Of Tufts College Compositions and methods for ocular delivery of a therapeutic agent

Also Published As

Publication number Publication date
US20160022646A1 (en) 2016-01-28
PT2968650T (pt) 2019-02-12
CA2900840C (en) 2023-03-28
JP2016517427A (ja) 2016-06-16
JP2022009275A (ja) 2022-01-14
AU2017210543B2 (en) 2019-01-31
RU2018128980A (ru) 2018-11-05
US9446026B2 (en) 2016-09-20
US10092549B2 (en) 2018-10-09
PH12019501902A1 (en) 2021-03-01
ZA201907176B (en) 2022-12-21
EP2968650B1 (en) 2019-01-16
AU2017210543A1 (en) 2017-08-17
SG10201710928PA (en) 2018-02-27
CN111789814B (zh) 2022-07-19
KR102433489B1 (ko) 2022-08-17
CN111789814A (zh) 2020-10-20
CN105142686B (zh) 2020-04-10
US20240325357A1 (en) 2024-10-03
US20160354349A1 (en) 2016-12-08
RU2768489C2 (ru) 2022-03-24
EP3520773A1 (en) 2019-08-07
MX2015012653A (es) 2016-08-18
PH12015501938A1 (en) 2016-01-11
DK2968650T3 (en) 2019-03-11
IL276016A (en) 2020-08-31
US20210196690A1 (en) 2021-07-01
JP6965308B2 (ja) 2021-11-10
KR20210132205A (ko) 2021-11-03
US20140303219A1 (en) 2014-10-09
JP2019167377A (ja) 2019-10-03
AU2014239252A1 (en) 2015-08-13
AU2019202857A1 (en) 2019-05-16
US10307404B1 (en) 2019-06-04
IL276016B (en) 2022-04-01
CN105142686A (zh) 2015-12-09
KR20150127256A (ko) 2015-11-16
TR201901462T4 (tr) 2019-02-21
BR112015021334B1 (pt) 2020-04-07
SG11201507316UA (en) 2015-10-29
MX386895B (es) 2025-03-19
BR112015021334A2 (pt) 2017-07-18
PH12015501938B1 (en) 2019-11-13
IL240510B (en) 2020-08-31
RU2018128980A3 (pl) 2022-01-11
JP6542193B2 (ja) 2019-07-10
RU2665953C2 (ru) 2018-09-05
RU2015143898A (ru) 2017-04-19
CA2900840A1 (en) 2014-09-25
IL240510A0 (en) 2015-10-29
ES2710152T3 (es) 2019-04-23
EP2968650A1 (en) 2016-01-20
US20190240201A1 (en) 2019-08-08
AU2014239252B2 (en) 2017-07-06
HK1216236A1 (en) 2016-10-28
SA516380321B1 (ar) 2019-01-16
US20190183864A1 (en) 2019-06-20
HUE042528T2 (hu) 2019-07-29
ZA201505447B (en) 2022-06-29
AU2019202857B2 (en) 2021-02-18
WO2014152661A1 (en) 2014-09-25
MX360888B (es) 2018-11-20
US20190247368A1 (en) 2019-08-15

Similar Documents

Publication Publication Date Title
IL276016B (en) Ocular formulations for administration of drug to the back of the eye
IL267997A (en) Preparations, formulations and methods for treating eye diseases
PT3811943T (pt) Composto para uso no tratamento de distúrbios oculares
IL240931A0 (en) History 3 - Phenylpropylamine is converted to the treatment of eye diseases and disorders
IL244687A0 (en) Epinephrine-based ophthalmic preparations for intraocular administration and methods for their production
IL282504A (en) Ocular formulations for drug administration and protection of the front part of the eye
EP3061455A4 (en) Therapeutic agent for ocular disease or prophylactic agent for ocular disease
SG11201600813VA (en) Method for producing anterior eye segment tissue
SG11201508026RA (en) Device providing enlargement & preventing collapse of the pupil of the eye
SG11201506882YA (en) Ophthalmic formulations
GB2541840B (en) Ophthalmic composition for the treatment of ocular infection
ZA201507718B (en) The local treatment of inflammatory ophthalmic diseases
GB2571647B (en) The use of dipropylene/diethylene glycol dibenzoate to reduce eye irritation
GB2520410B (en) Digital applanation tonometer
GB201303131D0 (en) Ocular prosthesis
GB201306413D0 (en) The local treatment of ophthalmic diseases
HK1227313A1 (en) Epinephrine-based ophthalmic compositions for intraocular administration and methods for fabricating thereof
EP3170500A4 (en) Prophylactic or therapeutic agent for diseases of posterior segment of eye